# Medical Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN-TD
- Date: 1979-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatriz Lozano, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Naomi Fairweather, MD

## Reason for consultation

Woman of 45, five and a half months after right total mastectomy for stage IA hormone receptor-positive, HER2-negative breast cancer, on tamoxifen since one month after surgery and now moving her survivorship care to primary care at this center. Please review the adjuvant endocrine plan and advise on hot flashes, surveillance, and genetic assessment, so that we can share her follow-up. **S**

## History

Ms. Lorde is seen at the request of Dr. Fairweather to share her survivorship care. She found a right breast lump at self-examination last September; a core biopsy showed invasive ductal carcinoma, and she had a right total mastectomy with flat closure and sentinel node biopsy at the end of September. She chose not to have reconstruction or wear a prosthesis, and this is respected. She has taken tamoxifen 20 mg daily for five months with three or four hot flashes a day, no abnormal vaginal bleeding, and no leg swelling or breathlessness. Her periods are regular. She has no bone pain, cough, headaches, abdominal pain, or new lumps. She walks and writes daily. She asked for the reasoning behind each recommendation. **S**

## Examination

| System | Finding |
|---|---|
| General | Well |
| Breasts and chest wall | Right chest wall flat, scar healed, no nodules; left breast without masses |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | No arm swelling; calves soft and non-tender |
| Abdomen | Soft; liver not enlarged |

BP 122/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 72.4 kg; BMI 25.7 kg/m². All vital signs are synthetic.

## Data reviewed

Outside diagnostic mammogram and ultrasound reports; core biopsy and mastectomy pathology with ER, PR, HER2, and Ki-67; sentinel node pathology (0 of 2); the 21-gene recurrence score of 14; her medication list; and the PHQ-9 and GAD-7 from Dr. Fairweather's visit three weeks ago. 

## Assessment

1. **Stage IA (pT1c pN0) hormone receptor-positive, HER2-negative right breast cancer after mastectomy** (C50.411). Low risk of recurrence: small, node-negative, grade 2, with a recurrence score of 14, so chemotherapy is not indicated. Radiation is not needed after mastectomy with clear margins and negative nodes. For a premenopausal woman at this risk, tamoxifen alone is standard; ovarian function suppression adds benefit mainly at higher risk and is not recommended for her. An aromatase inhibitor would need ovarian suppression while she is premenopausal. **S**
2. **Tamoxifen side effects** (Z79.810). Mild hot flashes, common in the first year and often easing. Medicines that strongly inhibit CYP2D6 (paroxetine, fluoxetine, bupropion) may reduce the activation of tamoxifen and should be avoided. **S**
3. **Surveillance**. For stage I to III breast cancer without symptoms, follow-up is history, examination, and a yearly mammogram of the remaining breast. Routine blood counts, chemistry, tumor markers, and body imaging do not improve survival and are not recommended. Breast MRI is for women who meet high-risk criteria. **S**
4. **Germline genetic assessment**. Testing is recommended for all patients with breast cancer diagnosed at 65 or younger, and she was 44. A pathogenic variant would change her surveillance (adding breast MRI and possibly gynecologic risk reduction) and would matter to her relatives; a negative result would leave her plan unchanged. **S**

## Recommendations

1. Continue tamoxifen 20 mg daily for at least five years, and consider ten years at the five-year review; no ovarian function suppression, aromatase inhibitor, or chemotherapy.
2. Hot flashes: non-drug measures first (cooling, layered clothing, paced breathing, cognitive behavioral strategies); if they disturb sleep, venlafaxine 37.5 mg daily; avoid paroxetine, fluoxetine, and bupropion.
3. Surveillance: cancer-related history and examination every three to six months for three years, then every six to twelve months to year five, then yearly; diagnostic mammogram of the left breast in September and yearly thereafter; no routine laboratory tests, tumor markers, or body imaging unless symptoms arise.
4. Genetic counseling with multigene panel germline testing now.
5. Primary care to ask at every visit about abnormal vaginal bleeding and symptoms of a clot, and to arrange a yearly gynecologic assessment; no routine pelvic ultrasound or endometrial biopsy without symptoms; no bone density test while she is premenopausal on tamoxifen alone.
6. Lymphedema risk is low after sentinel node biopsy alone; check the arm at visits and refer to a lymphedema therapist if swelling appears.
7. A written survivorship care plan by one year after diagnosis, with at least 150 minutes of activity a week, alcohol at or below one drink a day, and screening for distress at intervals.
8. Her decision not to have reconstruction or wear a prosthesis is recorded; no further discussion unless she raises it.

## Strengths and supports

- Supports: her family and a wide circle of writers and friends **S**

## Communication

Discussed with Dr. Fairweather today; the patient agrees with the plan and was given the reasoning in writing, as she asked. **S**

## Follow-up

Medical oncology review twice a year, alternating with primary care visits every three months in the first year. Primary care coordinates the mammogram, genetic counseling, gynecologic assessment, and distress screening. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol 2013;31(7):961-965 (2013), American Society of Clinical Oncology
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge
